A Phase II Trial of Trebananib (AMG 386; IND#111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium: An NRG/Gynecologic Oncology Group Trial

OBJECTIVES: Ang1&2 (angiopoietin-1; -2) interact with Tie2 receptors on endothelial cells to mediate vascular remodeling in an angiogenesis signaling pathway distinct from the VEGF axis. Trebaninib is a peptide Fc fusion protein that binds Ang1 and 2 and prevents interaction with Tie2. The effic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Moore, Kathleen N., Sill, Michael W., Tenney, Meaghan E., Darus, Christopher J., Griffin, David, Werner, Theresa L., Rose, Peter G., Behrens, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4692151/
https://ncbi.nlm.nih.gov/pubmed/26171911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados